<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37287983</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Elevated serum levels of human epididymis protein 4 in adult patients with proliferative lupus nephritis.</ArticleTitle><Pagination><StartPage>1179986</StartPage><MedlinePgn>1179986</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1179986</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1179986</ELocationID><Abstract><AbstractText Label="BACKGROUND">This study aimed to access whether serum human epididymis protein 4 (HE4) level could identify lupus nephritis (LN) pathological classes in adults and children.</AbstractText><AbstractText Label="METHODS">The serum HE4 levels of 190 healthy subjects and 182 patients with systemic lupus erythematosus (SLE) (61 adult-onset LN [aLN], 39 childhood-onset LN [cLN], and 82 SLE without LN) were determined using Architect HE4 kits and an Abbott ARCHITECT i2000SR Immunoassay Analyzer.</AbstractText><AbstractText Label="RESULTS">Serum HE4 level was significantly higher in the aLN patients (median, 85.5 pmol/L) than in the patients with cLN (44 pmol/L, <i>P</i> &lt; 0.001) or SLE without LN (37 pmol/L, <i>P</i> &lt; 0.001), or the healthy controls (30 pmol/L, <i>P</i> &lt; 0.001). Multivariate analysis showed that serum HE4 level was independently associated with aLN. Stratified by LN class, serum HE4 level was significantly higher in the patients with proliferative LN (PLN) than in those with non-PLN, and this difference was found only in aLN (median, 98.3 <i>versus</i> 49.3 pmol/L, <i>P</i> = 0.021) but not in cLN. Stratified by activity (A) and chronicity (C) indices, the aLN patients with class IV (A/C) possessed significantly higher serum HE4 levels than those with class IV (A) (median, 195.5 <i>versus</i> 60.8 pmol/L, <i>P</i> = 0.006), and this difference was not seen in the class III aLN or cLN patients.</AbstractText><AbstractText Label="CONCLUSION">Serum HE4 level is elevated in patients with class IV (A/C) aLN. The role of HE4 in the pathogenesis of chronic lesions of class IV aLN needs further investigation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Li, Xu, Le, Li, Shi, Zhu, Xu, Li, Liu, Wang and Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Liubing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Huiya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Runzhao</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hongji</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hongxu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Laisheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">active/chronic lesions</Keyword><Keyword MajorTopicYN="N">diagnostic efficacy</Keyword><Keyword MajorTopicYN="N">pathological classes</Keyword><Keyword MajorTopicYN="N">proliferative lupus nephritis</Keyword><Keyword MajorTopicYN="N">serum HE4</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37287983</ArticleId><ArticleId IdType="pmc">PMC10243370</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1179986</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis (2023). doi: 10.1136/ard-2022-223741</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223741</ArticleId><ArticleId IdType="pubmed">36792346</ArticleId></ArticleIdList></Reference><Reference><Citation>Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J. Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California lupus surveillance project. Arthritis Care Res (Hoboken) (2020) 72:622&#x2013;9. doi: 10.1002/acr.23887</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23887</ArticleId><ArticleId IdType="pmc">PMC6872905</ArticleId><ArticleId IdType="pubmed">31115180</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto T, Niewold TB. Genetics of human lupus nephritis. Clin Immunol (2017) 185:32&#x2013;9. doi: 10.1016/j.clim.2016.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.09.012</ArticleId><ArticleId IdType="pmc">PMC5373939</ArticleId><ArticleId IdType="pubmed">27693588</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrisca B, Sorohan B, Tuta L, Ismail G. Advances in lupus nephritis pathogenesis: from bench to bedside. Int J Mol Sci (2021) 22 :3766. doi: 10.3390/ijms22073766</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073766</ArticleId><ArticleId IdType="pmc">PMC8038540</ArticleId><ArticleId IdType="pubmed">33916456</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. . 2019 Update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis (2020) 79:713&#x2013;23. doi: 10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatol (Oxford) (2020) 59:v39&#x2013;51. doi: 10.1093/rheumatology/keaa381</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa381</ArticleId><ArticleId IdType="pmc">PMC7751166</ArticleId><ArticleId IdType="pubmed">33280015</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljaberi N, Bennett M, Brunner HI, Devarajan P. Proteomic profiling of urine: implications for lupus nephritis. Expert Rev Proteomics (2019) 16:303&#x2013;13. doi: 10.1080/14789450.2019.1592681</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2019.1592681</ArticleId><ArticleId IdType="pmc">PMC6693508</ArticleId><ArticleId IdType="pubmed">30855196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Teng YKO, Saxena R, Tanaka Y. Treatment of lupus nephritis: consensus, evidence and perspectives. Nat Rev Rheumatol (2023) 19 :227-38. doi: 10.1038/s41584-023-00925-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-023-00925-5</ArticleId><ArticleId IdType="pubmed">36864291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocaoglu M, Valenzuela-Almada MO, Dabit JY, Osei-Onomah SA, Chevet B, Giblon RE, et al. . Incidence, prevalence, and mortality of lupus nephritis: a population-based study over four decades using the lupus Midwest network. Arthritis Rheumatol (2022) 75 :567-73. doi: 10.1136/lupus-2021-lupus21century.30</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-lupus21century.30</ArticleId><ArticleId IdType="pmc">PMC10065880</ArticleId><ArticleId IdType="pubmed">36227575</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun (2022) 132:102871. doi: 10.1016/j.jaut.2022.102871</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102871</ArticleId><ArticleId IdType="pubmed">35999111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Timsit JF, Perrozziello A, Ruckly S, Dupuis C, Bouadma L, et al. . The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev (2019) 18:733&#x2013;7. doi: 10.1016/j.autrev.2019.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.05.011</ArticleId><ArticleId IdType="pubmed">31059847</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant (2012) 27:3248&#x2013;54. doi: 10.1093/ndt/gfs073</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfs073</ArticleId><ArticleId IdType="pubmed">22523116</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 65:521&#x2013;30. doi: 10.1111/j.1523-1755.2004.00443.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, et al. . Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis (2018) 77:1318&#x2013;25. doi: 10.1136/annrheumdis-2017-212732</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212732</ArticleId><ArticleId IdType="pubmed">29730634</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis (2003) 62:435&#x2013;9. doi: 10.1136/ard.62.5.435</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.5.435</ArticleId><ArticleId IdType="pmc">PMC1754523</ArticleId><ArticleId IdType="pubmed">12695156</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. . Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 71:1771&#x2013;82. doi: 10.1136/annrheumdis-2012-201940</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201940</ArticleId><ArticleId IdType="pmc">PMC3465859</ArticleId><ArticleId IdType="pubmed">22851469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. . American College of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 64:797&#x2013;808. doi: 10.1002/acr.21664</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. . Revision of the international society of Nephrology/Renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int (2018) 93:789&#x2013;96. doi: 10.1016/j.kint.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Fenaroli P, Rosenberg A, Bagnasco S, Li J, Monroy-Trujillo J, et al. . History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis. Rheumatol (Oxford) (2021) 61 :2483-93. doi: 10.1093/rheumatology/keab775</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab775</ArticleId><ArticleId IdType="pmc">PMC9308381</ArticleId><ArticleId IdType="pubmed">34664621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercadal L, Montcel ST, Nochy D, Queffeulou G, Piette JC, Isnard-Bagnis C, et al. . Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant (2002) 17:1771&#x2013;8. doi: 10.1093/ndt/17.10.1771</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/17.10.1771</ArticleId><ArticleId IdType="pubmed">12270983</ArticleId></ArticleIdList></Reference><Reference><Citation>Preda A, Van Dijk LC, Van Oostaijen JA, Pattynama PM. Complication rate and diagnostic yield of 515 consecutive ultrasound-guided biopsies of renal allografts and native kidneys using a 14-gauge biopty gun. Eur Radiol (2003) 13:527&#x2013;30. doi: 10.1007/s00330-002-1482-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-002-1482-3</ArticleId><ArticleId IdType="pubmed">12594555</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Wu T, Xie C, Vanarsa K, Han J, Mahajan T, et al. . Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther (2012) 14:R164. doi: 10.1186/ar3912</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3912</ArticleId><ArticleId IdType="pmc">PMC3580557</ArticleId><ArticleId IdType="pubmed">22788914</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran LH, Graulus GJ, Vincke C, Smiejkowska N, Kindt A, Devoogdt N, et al. . Nanobodies for the early detection of ovarian cancer. Int J Mol Sci 23 (2022) 23 :13687. doi: 10.3390/ijms232213687</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232213687</ArticleId><ArticleId IdType="pmc">PMC9691119</ArticleId><ArticleId IdType="pubmed">36430166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci (2022) 23 :12041. doi: 10.3390/ijms24010002</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24010002</ArticleId><ArticleId IdType="pmc">PMC9569881</ArticleId><ArticleId IdType="pubmed">36233339</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy B, Jr., Nagy B, Fila L, Clarke LA, Gonczy F, Bede O, et al. . Human epididymis protein 4: a novel serum inflammatory biomarker in cystic fibrosis. Chest (2016) 150:661&#x2013;72. doi: 10.1016/j.chest.2016.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2016.04.006</ArticleId><ArticleId IdType="pubmed">27105680</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBleu VS, Teng Y, O'Connell JT, Charytan D, Muller GA, Muller CA, et al. . Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med (2013) 19:227&#x2013;31. doi: 10.1038/nm.2989</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2989</ArticleId><ArticleId IdType="pmc">PMC4457508</ArticleId><ArticleId IdType="pubmed">23353556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Ren Y, He X. IFN-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol (2021) 12:676082. doi: 10.3389/fimmu.2021.676082</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676082</ArticleId><ArticleId IdType="pmc">PMC8093624</ArticleId><ArticleId IdType="pubmed">33959133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 40:1725. doi: 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Xie J, Lin F, Luo W, Zhang Z, Mao P, et al. . Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: a prospective cohort study. Int Immunopharmacol (2018) 60:189&#x2013;93. doi: 10.1016/j.intimp.2018.04.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.04.048</ArticleId><ArticleId IdType="pubmed">29747124</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Zhang Z, Qin B, Wu P, Zhong R, Zhou L, et al. . Human epididymis protein 4: a novel biomarker for lupus nephritis and chronic kidney disease in systemic lupus erythematosus. J Clin Lab Anal (2016) 30:897&#x2013;904. doi: 10.1002/jcla.21954</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.21954</ArticleId><ArticleId IdType="pmc">PMC6807143</ArticleId><ArticleId IdType="pubmed">27075413</ArticleId></ArticleIdList></Reference><Reference><Citation>Maria NI, Davidson A. Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat Rev Rheumatol (2020) 16:255&#x2013;67. doi: 10.1038/s41584-020-0401-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0401-9</ArticleId><ArticleId IdType="pubmed">32203285</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol (2016) 12:143&#x2013;53. doi: 10.1038/nrrheum.2015.159</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.159</ArticleId><ArticleId IdType="pmc">PMC4820834</ArticleId><ArticleId IdType="pubmed">26581344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, Chen J, Wu J, Gu Y, Huang Q, Deng Z, et al. . Human epididymis protein 4 aggravates airway inflammation and remodeling in chronic obstructive pulmonary disease. Respir Res (2022) 23:120. doi: 10.1186/s12931-022-02040-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02040-7</ArticleId><ArticleId IdType="pmc">PMC9097053</ArticleId><ArticleId IdType="pubmed">35550579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ren YL, Chang J, Gu L, Sun LY, Systematic Review A. And meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol (2018) 33:17&#x2013;25. doi: 10.5606/ArchRheumatol.2017.6127</Citation><ArticleIdList><ArticleId IdType="doi">10.5606/ArchRheumatol.2017.6127</ArticleId><ArticleId IdType="pmc">PMC5864167</ArticleId><ArticleId IdType="pubmed">29900975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JY, Yeh KW, Huang JL. Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions. Semin Arthritis Rheum (2014) 43:513&#x2013;20. doi: 10.1016/j.semarthrit.2013.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2013.07.005</ArticleId><ArticleId IdType="pubmed">23972330</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. a study based on the classification of the world health organization. Am J Med (1987) 83:877&#x2013;85. doi: 10.1016/0002-9343(87)90645-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(87)90645-0</ArticleId><ArticleId IdType="pubmed">3674094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Mohan C. Urinary biomarkers in lupus nephritis: are we there yet? Arthritis Rheumatol (2021) 73:194&#x2013;6. doi: 10.1002/art.41508</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41508</ArticleId><ArticleId IdType="pubmed">32892509</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Sun F, Bao H, Liang L, Zhan M, Yao H, et al. . Elevated serum human epididymis protein 4 is associated with disease activity and systemic involvements in primary sjogren's syndrome. Front Immunol (2021) 12:670642. doi: 10.3389/fimmu.2021.670642</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.670642</ArticleId><ArticleId IdType="pmc">PMC8260678</ArticleId><ArticleId IdType="pubmed">34248951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Zhang L, E L, Xu K, Wang XF, Zhang B, et al. . Increased levels of HE4 (WFDC2) in systemic sclerosis: a novel biomarker reflecting interstitial lung disease severity? Ther Adv Chronic Dis (2020) 11 :2040622320956420. doi: 10.1177/2040622320956420</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040622320956420</ArticleId><ArticleId IdType="pmc">PMC7488885</ArticleId><ArticleId IdType="pubmed">32963750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, et al. . Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney Int (2010) 77:820&#x2013;9. doi: 10.1038/ki.2010.13</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2010.13</ArticleId><ArticleId IdType="pubmed">20182417</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Wang F, Wan J, Ye Z, Huang C, Cai Y, et al. . Serum human epididymis secretory protein 4 as a potential biomarker of renal fibrosis in kidney transplantation recipients. Clin Chim Acta (2018) 483:216&#x2013;21. doi: 10.1016/j.cca.2018.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2018.05.006</ArticleId><ArticleId IdType="pubmed">29738696</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Yang Q, Li X, Qin Y. Potential association between elevated serum human epididymis protein 4 and renal fibrosis: a systemic review and meta-analysis. Med (Baltimore) (2017) 96:e7824. doi: 10.1097/MD.0000000000007824</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000007824</ArticleId><ArticleId IdType="pmc">PMC6392936</ArticleId><ArticleId IdType="pubmed">28885334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>